Recombinant Vaccine Production: Production of a Recombinant CCHF MVA Vaccine

One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.